
    
      This is a Phase 2 study designed to evaluate the safety and efficacy of ABT-384 in
      approximately 260 adults with mild-to-moderate Alzheimer's Disease (AD). Subjects will be
      randomized to one of four treatment groups (ABT-384, donepezil, or placebo) for a 12-week
      Treatment Period.
    
  